Moleculin Biotech (MOL) Ratios
Moleculin Biotech Ratios
DE:MOL's free cash flow for Q2 2026 was $-6.66M. For the 2026 fiscal year, DE:MOL's free cash flow was increased by $0.00 and operating cash flow was $-6.66M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.41 | 0.97 | 3.86 | 9.46 | 20.02 |
| Quick Ratio | 1.41 | 0.97 | 3.86 | 9.46 | 20.02 |
| Cash Ratio | 1.30 | 0.80 | 3.46 | 8.95 | 19.58 |
| Solvency Ratio | -4.70 | -1.98 | -2.44 | -5.52 | -3.09 |
| Operating Cash Flow Ratio | -3.32 | -4.45 | -3.54 | -5.74 | -5.23 |
| Short-Term Operating Cash Flow Coverage | -165.95 | 0.00 | 0.00 | 0.00 | -197.41 |
| Net Current Asset Value | $ 2.57M | $ -5.75M | $ 14.13M | $ 40.37M | $ 67.40M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.03 | 0.02 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.02 | 0.08 | 0.02 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.02 | 0.07 | 0.02 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.47 | 2.83 | 1.47 | 1.10 | 1.06 |
| Debt Service Coverage Ratio | -244.31 | 0.00 | 0.00 | 0.00 | -237.54 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 6.06 | 3.47 | 7.26 | 5.91 | 2.22 |
| Net Debt to EBITDA | 0.25 | 0.18 | 0.78 | 1.40 | 3.10 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 133.69% | 81.69% | 100.47% | 94.73% | 69.20% |
| Return on Assets (ROA) | -151.68% | -128.58% | -77.89% | -50.55% | -18.90% |
| Return on Equity (ROE) | -223.64% | -363.99% | -114.18% | -55.61% | -20.12% |
| Return on Capital Employed (ROCE) | -164.37% | -230.34% | -94.36% | -58.25% | -28.54% |
| Return on Invested Capital (ROIC) | -162.91% | -227.97% | -94.06% | -58.12% | -28.51% |
| Return on Tangible Assets | -305.70% | -376.72% | -109.97% | -62.72% | -21.79% |
| Earnings Yield | -855.93% | -371.82% | -116.99% | -95.73% | -31.79% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -14226.89 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 14226.89 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -383.86 | -173.26 | -304.98 | -362.35 | -264.42 |
| Free Cash Flow Per Share | -383.86 | -173.36 | -306.55 | -363.22 | -264.69 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -1835.54 | -194.36 | -412.52 | -997.42 |
| Capital Expenditure Coverage Ratio | 0.00 | -1835.54 | -194.36 | -412.52 | -997.42 |
| Operating Cash Flow Coverage Ratio | -63.33 | -49.92 | -41.99 | -61.28 | -119.19 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -579.84% | -407.90% | -95.20% | -91.38% | -37.95% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.12 | -0.22 | -0.85 | -1.04 | -3.15 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.26 | 0.98 | 0.98 | 0.58 | 0.63 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.17 | -0.25 | -1.05 | -1.09 | -2.64 |
| Price-to-Operating Cash Flow Ratio | -0.17 | -0.25 | -1.06 | -1.10 | -2.64 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | 0.87 | -0.01 | 0.05 |
| Enterprise Value Multiple | 0.14 | -0.09 | -0.08 | 0.41 | 0.91 |
| Enterprise Value | -4.60M | 2.05M | 2.47M | -12.37M | -20.75M |
| EV to EBITDA | 0.14 | -0.09 | -0.08 | 0.41 | 0.91 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.20 | -0.09 | -0.10 | 0.45 | 1.09 |
| EV to Operating Cash Flow | 0.20 | -0.09 | -0.10 | 0.45 | 1.10 |
| Tangible Book Value Per Share | 65.14 | -37.53 | 188.87 | 538.07 | 946.64 |
| Shareholders’ Equity Per Share | 253.36 | 43.41 | 329.94 | 684.22 | 1102.19 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -566.62 | -158.02 | -376.71 | -380.52 | -221.77 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 0.95 | 0.69 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.68 | 1.10 | 0.81 | 0.95 | 1.19 |
Currency in USD